PP-001

Panoptes Pharma GmbH · Phase 1 active Small molecule

At a glance

Generic name	PP-001
Sponsor	Panoptes Pharma GmbH
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis (PHASE1, PHASE2)
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PP-001 CI brief — competitive landscape report
PP-001 updates RSS · CI watch RSS
Panoptes Pharma GmbH portfolio CI